ArticleMultiple sclerosis journal - experimental, translational and clinical

Fingolimod versus interferon beta 1-a: Benefit-harm assessment approach based on TRANSFORMS individual patient data.

Alessandra Spanu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.